Low Molecular Weight Heparin Prescribing and Administration (Adults)
|
|
- Merry Baldwin
- 6 years ago
- Views:
Transcription
1 Clinical guideline Lw Mlecular Weight Heparin Prescribing and Administratin (Adults) The Natinal Patient Safety Agency issued guidance n ways f reducing dsing errrs when prescribing lw mlecular weight heparins (LMWH) in July The main issues highlighted include 1 : Lack f cnsideratin f patients accurate weight befre dsing The dse f LMWH may still be miscalculated based n the knwn weight LMWH dses and frequencies are smetimes used utside guideline recmmendatins fr the required clinical indicatin r ther predispsing factrs such as renal failure. Limited infrmatin is cmmunicated during transfer f care i.e. indicatin, dsage, intended duratin f treatment and the patient s weight. This guideline is t prvide infrmatin t supprt the safe and apprpriate use f LMWHs acrss bth secndary and primary care. Chice f LMWH The chice f lw mlecular weight heparin used at Wirral University Teaching Hspital (WUTH) depends n the indicatin f treatment and the patient s renal functin. Indicatin Renal functin Chice f LMWH Venus thrmbemblism (VTE) prphylaxis and treatment all areas (except trauma and rthpaedics) VTE prphylaxis trauma and rthpaedics Acute crnary syndrme (ACS) alne (i.e. n ther indicatins requiring full anticagulatin) Irrespective f renal functin CrCl 15ml/min CrCl <15ml/min) CrCl 20ml/min CrCl <20ml/min Enxaparin Apixaban Enxaparin *Fndaparinux Enxaparin ACS plus ther indicatins requiring full anticagulatin (e.g. mechanical prsthetic valves, treatment f VTE r atrial fibrillatin requiring high level anticagulatin) Irrespective f renal functin Enxaparin *Fndaparinux is a synthetic pentasaccharide that inhibits factr Xa. CrCl = Creatinine Clearance Page 1 f 10
2 Dsing cnsideratins Renal functin A patient s renal functin shuld be cnsidered befre prescribing a LMWH as this may affect the chice and the dse f LMWH. Hwever, this shuld nt delay initiatin f treatment but every effrt must be made t calculate subsequent dse based n this infrmatin. Renal functin shuld be checked befre starting treatment and then at apprpriate intervals if cntinuing n LMWH (i.e. rutinely every 3 mnths r sner if the patient s cnditin changes in a way that might affect renal functin). A patient s estimated creatinine clearance can be calculated using Cckcrft and Gault s equatin. Cckcrft and Gault equatin fr creatinine clearance Creatinine clearance (ml/min) = Y x (140-age) x weight Where Y = 1.23 fr males and 1.04 fr females Serum creatinine uml/l Fr bese patients, adjusted bdy weight shuld be used Adjusted bdy weight = ideal bdy weight x (actual bdy weight ideal bdy weight) Ideal bdy weight (IBW) shuld be used t calculate the creatinine clearance unless patients are underweight. IBW can be calculated using the fllwing equatin: IBW Females = [45.5kg + (2.3 x every inch ver 5ft)] kg IBW Males = [50kg + (2.3 x every inch ver 5ft)] kg Fr underweight patients use actual bdy weight. An nline creatinine clearance calculatr is available at: N.B: Renal functin may be reprted as estimated Glmerular Filtratin Rate (egfr) (in ml/min/1.73m 2 ) which is nt equivalent t the estimates f creatinine clearance described abve (reprted in ml/min). Since egfr estimates have nt yet been validated fr drug dsing, dse adjustment fr renal impairment cntinues t be based n estimates f creatinine clearance (e.g. calculated frm the Cckcrft and Gault equatin r frm a 24-hur urine cllectin) Weight Treatment dses f LMWHs are calculated based n the patient s weight. Therefre, where pssible, an accurate weight (in kg) shuld be btained using validated weighing equipment by persnnel trained in using the weighing equipment. In exceptinal circumstances, when a patient cannt be weighed, bdy weight infrmatin can be btained frm the patient r carer. Hwever, if this infrmatin cannt be btained, as a last resrt, the weight may be estimated by the prescriber. The patient s weight shuld be dcumented in the clinical ntes (medical r nursing ntes r GP clinical system) AND the hspital prescribing system (when in use) r the cmmunity patient medicatin administratin chart (PMAC) at the start f the treatment. The patient s weight shuld be added t the FP10 prescriptin. This is required by the cmmunity pharmacist when assessing the dse. It shuld then be rechecked at apprpriate intervals, at least every 3 mnths r sner if the patient s clinical cnditin changes in a way that might affect their bdy weight. Every effrt shuld be made t ensure an accurate weight (in kg) is btained prir t a LMWH being prescribed but this shuld nt delay treatment. If it is nt pssible t weigh the patient, r an estimated weight is used t calculate the dse f LMWH, this shuld be made clear in the patient s clinical ntes and re-assessed at a later date if apprpriate. Page 2 f 10
3 Preventin f venus thrmbemblism Duratin LMWH shuld cntinue t be administered fr as lng as the patient remains at risk f venus thrmbemblism (VTE). Calculating the right dse ALL patients wh are admitted t hspital MUST have their risk f develping a venus thrmbemblism (VTE) assessed n admissin, reassessed within 24 hurs f admissin and whenever the clinical situatin changes 2. PCIS will prvide guidance n the chice f LMWH and dse depending n the patient s renal functin (and patient s weight if their CrCl <30ml/min). Fr areas that d nt use PCIS, please refer t Table 1 fr dsing infrmatin. Table 1 Dses f enxaparin fr prphylaxis against VTE Indicatin LMWH Dse fr patients with a creatinine clearance 30mL/min Dse fr patients with creatinine clearance <30ml/min Medical thrmbprphylaxis 40mg sc nce daily 20mg sc nce daily Surgical thrmbprphylaxis*- Mderate risk Enxaparin 20mg sc nce daily 20mg sc nce daily Surgical thrmbprphylaxis*- High risk 40mg sc nce daily *Fr VTE prphylaxis in rthpaedic patients please refer t Trauma and Orthpaedic Venthrmbemblic (VTE) Prphylaxis Guidelines n the intranet. VTE prphylaxis in pregnancy Fr prphylaxis f VTE in pregnancy please refer t Wirral Wmen and Children s Guideline n 33: Venus Thrmbemblism Prphylaxis and Treatment. Page 3 f 10
4 Treatment f VTE Duratin Fr the initial treatment f VTE, a LMWH shuld be cntinued fr at least 6 days AND until an ral anticagulant (if used) is established i.e. until the patient s INR is in the specified therapeutic range. Shrt term therapy with LMWH Althugh ral anticagulatin is preferred fr the treatment f VTE, LMWHs shuld be cnsidered fr up t 6 weeks fr the small subgrup f patients: And With very lw risk VTE ( i.e. thse wh suffered a belw knee DVT fr which there were likely precipitating factrs) Fr whm ral anticagulatin appears unjustified r inapprpriate, 3 such as thse with: (list nt exhaustive) - Pr cmpliance, cgnitive impairment, chatic lifestyle* r recreatinal drug misuse* - Increased bleeding risk (e.g. due t falls, peptic ulcer disease) - Liver dysfunctin (indicated by elevated INR >1.2) NOTE: This will be a very small subgrup f patients *Fr patients with chatic lifestyle r recreatinal drug misuse, the risks in treating these patients with LMWH shuld be cnsidered e.g. safe sharps dispsal Extended (>6weeks) r lng term (indefinite) LMWH therapy A LMWH may be cnsidered fr lnger perids in patients wh are at higher risk f VTE than the very lw risk VTE grup described abve and fr whm ral anticagulant may be unsuitable (as utlined abve). It may als be cnsidered fr patients with an active malignancy (within 6 mnths f malignancy diagnsis r treatment) r t prevent r treat a VTE in pregnant wmen. NOTE: The use f LMWHs fr lnger than 6 weeks is nt licensed Any decisin t ffer a LMWH n discharge shuld be made by a cnsultant and will be made mst frequently by the cnsultant acute physician r cnsultant n-call fr the acute take. The n-call cnsultant haematlgist is als available t discuss cmplex cases. Fr patients being discharged n extended (>6weeks) r lng term (indefinite) LMWH due t pr cmpliance, this decisin MUST be made by the cnsultant r ther senir medical staff and this shuld be clearly dcumented in the patients medical ntes. If this is nt clearly dcumented in the patient s medical ntes, then it will be queried by the pharmacist n discharge. It shuld be nted that GPs may ffer useful cmments n patients scial factrs. In mst instances, patients receiving LMWH therapy beynd 3 mnths shuld be under the care f a cnsultant haematlgist fr cnsideratin f anti-factr Xa mnitring, bne densitmetry and steprsis prphylaxis. Calculating the right dse At WUTH, PCIS prvides guidance n the chice f LMWH and dse depending n the patient s indicatin, weight and renal functin. Fr areas that d nt use PCIS, refer t Table 2a/2b (verleaf) fr dsing infrmatin. Page 4 f 10
5 1. If the patient s creatinine clearance is 30mL/min Enxaparin 1.5mg/kg, by SC injectin, nce daily. There are different size graduated syringes. Select the mst apprpriate size t give the required dse. Table 2a. Dses f enxaparin fr the initial treatment f DVT/PE if CrCl 30ml/min Bdy weight (kg) Daily dse (mg) Syringe Type mg/0.6ml (ne range syringe) mg/0.8ml (ne brwn syringe) mg/1ml (ne grey syringe) mg/0.8ml (ne lilac syringe) mg/1ml (ne grey syringe) AND 40mg/0.4ml (ne yellw syringe) mg/1ml (ne blue syringe) mg/1ml (ne grey syringe) AND 60mg/0.6ml (ne range syringe) mg/1ml (ne grey syringe) AND 80mg/0.8ml (ne brwn syringe) * 100mg/1ml (Tw grey syringes) * 100mg/1ml (ne grey syringe) AND 120mg/0.8ml (ne lilac syringe) * Antifactr Xa levels need t be taken after the 3 rd r 4 th dse and dses adjusted accrdingly after discussin with haematlgy when required. Page 5 f 10
6 2. If the patient s creatinine clearance is <30mL/min Enxaparin 1mg/kg, by SC injectin, nce daily. There are different size graduated syringes. Select the mst apprpriate size t give the required dse. Table 2b. Dses f enxaparin fr the initial treatment f DVT/PE if CrCl <30ml/min Syringe size Bdy weight Daily dse Injectin vlume 40mg/0.4ml 40kg 40mg 0.4ml 60mg/0.6ml 50kg 50mg 0.5ml 60kg 60mg 0.6ml 80mg/0.8ml 70kg 70mg 0.7ml 80kg 80mg 0.8ml 100mg/1ml 90kg 90mg 0.9ml Cmbinatin f abve syringes 100kg 100mg 1ml 110kg 110mg 1.1ml 120kg 120mg 1.2ml 130kg 130mg 1.3ml 140kg 140mg 1.4ml 150kg 150mg 1.5ml Weight runded t nearest 10kg and 0.1ml VTE treatment in pregnancy Fr prphylaxis and treatment f VTE in pregnancy please refer t Wirral Wmen and Children s Guideline n 33: Venus Thrmbemblism Prphylaxis and Treatment Page 6 f 10
7 Cntraindicatins/Cautins t LMWH 4 D nt prescribe r administer LMWHs t patients wh have: Knwn hypersensitivity t active ingredients Current r previus histry f heparin-induced thrmbcytpenia. Hypersensitivity t benzyl alchl Generalised r lcal haemrrhagic tendency, including: uncntrlled severe hypertensin (i.e. BP >220/120mmHg as per British Hypertensin Sciety definitin) 5. The decisin n whether t use LMWH shuld be cnsidered n the balance f risk versus benefit. severe liver insufficiency active peptic ulcer acute r subacute septic endcarditis intracranial haemrrhage, r injuries peratins n the central nervus system, eyes and ears, and in wmen with abrtus imminens Patients shuld nt have an epidural inserted r remved r spinal inserted until at least 10 hurs have elapsed since the last dse f prphylactic LMWH. Prphylactic LMWH shuld nt be given within 2 hurs f epidural insertin r catheter remval. If insertin was difficult r bldy then prphylactic LMWH shuld nt be given within 4 hurs f insertin r remval. Treatment dses f LMWH must nt be given t patients wh have an epidural catheter in situ. Remve the epidural catheter and nly start the treatment dse f LMWH 4 hurs after the catheter has been remved. If the patient has had a spinal anaesthetic, d nt start treatment dses f LMWH until 4 hurs after the spinal was perfrmed. (see Acute Pain Guidelines). Prphylactic LMWH therapy is nt required if patients are already receiving therapeutic anticagulatin. Mnitring Fr patients receiving a LMWH fr lnger than 5 days, the fllwing shuld be mnitred: Platelets this is due t the risk f antibdy-mediated heparin-induced thrmbcytpenia (HIT). Mnitr platelets apprximately 7 t 10 days after initiatin and then 3 mnthly whilst LMWH treatment cntinues. Treatment shuld be stpped immediately in thse wh develp thrmbcytpenia. Signs f heparin-induced thrmbcytpenia include a 50% reductin f platelet cunt, thrmbsis r skin allergy. 6 Fr further infrmatin n diagnsis and management f HIT, see Heparin-induced Thrmbcytpenia (HIT): Diagnsis and management (adults). Ptassium LMWHs can cause hyperkalaemia due t suppressin f aldsterne secretin. Patients at higher risk f this include thse with diabetes mellitus, chrnic renal failure, pre-existing metablic acidsis, raised plasma ptassium r thse taking ptassium-sparing drugs. Mnitr ptassium apprximately 7 t 10 days after initiatin and then 3 mnthly thereafter whilst LMWH treatment cntinues (r sner if clinically indicated). Page 7 f 10
8 Administratin f LMWHs In hspital Nursing staff shuld ensure that an accurate weight in kg is dcumented in the medical r nursing ntes r hspital prescribing system t enable an apprpriate LMWH dse t be calculated. Where pssible, the nursing staff shuld ensure that the dse f LMWH has been verified by a pharmacist (indicated by a v n the current drugs list) befre it is given. If the weight, renal functin r pharmacist verificatin is nt available immediately, this shuld nt delay the initiatin f treatment but effrts shuld be made t ensure these are btained as sn as pssible. Fr discharge If the patient is required t self administer a LMWH, apprpriate training must be given prir t discharge. The patient needs t be deemed cmpetent by the nurse befre discharge. If the patient is unable t self-administer, a referral must be sent t the district nurse t cntinue administratin at hme after discharge. In this circumstance, a PMAC must als be filled in clearly by the prescriber befre discharge and clinically checked by pharmacist. Clinical requirements fr discharge It is the respnsibility f the ward prescriber AND cnsultant t ensure the indicatin, dse, duratin f treatment, patient s weight and renal functin is dcumented n the discharge letter. When clinically checking the discharge prescriptin, at minimum, the ward pharmacist must ensure that the abve infrmatin has been cmpleted by the prescriber and is available n the discharge letter. The ward pharmacist shuld then cmplete the checklist belw and endrse IDDA n the discharge prescriptin t indicate that the abve checks are cmplete befre any supplies f LMWH will be made n discharge. Up t 2 weeks supply f LMWH will be made by the hspital at discharge and then this shuld be cntinued by the patient s GP. Apprpriate Indicatin (if n extended duratin f LMWH due t pr cmpliance, must state in the ntes that the decisin has been apprved by the senir medical staff) Dse apprpriate fr the patient s renal functin and weight Duratin Apprpriately trained persn t Administer the LMWH in the cmmunity if the patient is unable t self-administer. Page 8 f 10
9 Prescribing LMWHs in the cmmunity Patients prescribed LMWHs in the cmmunity shuld have their weight and renal functin checked every 3 mnths (r sner if clinically indicated) and dcumented in their medical ntes. Prescribers must check the patient s weight and renal functin befre prescribing. Prescribers shuld use the dse calculatin tables 2a (see page 5) and 2b (see page 6) when calculating dses f enxaparin. If a patient medicatin administratin chart (PMAC) is required fr cmmunity nurse administratin, this must include the patient s weight and renal functin and be cmpleted in full by the prescriber. All prescriptins in the cmmunity shuld include the patient s weight. A prmpt will be added t Scriptswitch t facilitate this. Patients receiving a LMWH in the cmmunity fr >3mnths will usually be under the supervisin f a haematlgist. The patient s weight, renal functin and anti factr Xa level shuld be checked apprximately 3 mnthly t ensure the dse f LMWH is still apprpriate. The haematlgist will advise n any ptential dse change. The weight and renal functin shuld be reprted in the hspital crrespndence frm the Cnsultant Haematlgist t the GP. Requirements f cmmunity pharmacy Cmmunity pharmacists shuld check the fllwing befre dispensing a LMWH: Indicatin whether prphylaxis r treatment Duratin f treatment Weight f patient Renal functin Strength f syringe required Vlume f syringe required Dse in internatinal units and in millilitres Rute and frequency f administratin Requirements f cmmunity nurses Cmmunity nurses shuld check the fllwing befre administering a dse f LMWH Indicatin whether prphylaxis r treatment Duratin f treatment Weight f patient Renal functin Strength f syringe required Vlume f syringe required Dse in internatinal units and in millilitres Rute and frequency f administratin Page 9 f 10
10 References 1. Natinal Patient Safety Agency. Rapid Respnse Reprt. Reducing Treatment Dse Errrs with Lw Mlecular Weight Heparins. July Department f Health. Venus thrmbemblism risk assessment guidance (March 2010) nce/dh_ Accessed <08/01/11> 3. P Lmas, SC Smith, NM Butt. A retrspective audit f extended lw mlecular weight heparin (LMWH) therapy in patients deemed unsuitable fr warfarin at a large district general hspital. British Jurnal f Haematlgy, 149, (Suppl 1), Summary f Prduct Characteristics. Innhep. Le Pharma. and d+innhep+syringe+20%2c000+iu+ml/#contraindications (20,000units/ml strength) and d+innhep+syringe+10%2c000+iu+ml/ (10,000units/ml) <accessed 06/01/11> 5. B Williams, NR Pulter, et al. British Hypertensin Sciety Guidelines. Guidelines fr management f hypertensin: reprt f the furth wrking party f the British Hypertensin Sciety, 2004 BHS IV. Jurnal f Human Hypertensin (2004) 18, p British Natinal Frmulary nline. 60 th editin. Accessed <08/01/11> Wrking grup: Gareth Malsn, Medicines Management Pharmacist, WUTH Dr R. Dasgupta, Cnsultant Haematlgist, WUTH Page 10 f 10
Intravenous Vancomycin Use in Adults Intermittent (Pulsed) Infusion
Intravenus Vancmycin Use in Adults Intermittent (Pulsed) Infusin Backgrund This plicy cvers the use f intravenus vancmycin prescribed as an intermittent (pulsed) infusin. This can be used fr treatment
More informationIntravenous Vancomycin Use in Adults Intermittent (Pulsed) Infusion
Backgrund This plicy cvers the use f intravenus vancmycin prescribed as an intermittent (pulsed) infusin. This can be used fr treatment r prphylaxis. Evidence supprting this guidance is detailed belw.
More informationCambridge Breast Unit Protocols for anticoagulant management prior to breast or axillary biopsies or excisions.
Prtcl CBU/POL/ JOINT POLICIES/008 Octber 2017 Prtcls fr anticagulant management prir t breast r axillary bipsies r excisins. 1. Scpe Fr use in the in bth screening and symptmatic breast services. 2. Purpse
More informationUS Public Health Service Clinical Practice Guidelines for PrEP
Webcast 1.3 US Public Health Service Clinical Practice Guidelines fr PrEP P R E S ENTED BY: M A R K T H R U N, M D A S S O C I AT E P R O F E S S O R, U N I V E R S I T Y O F C O L O R A D O, D I V I S
More informationCompleting the NPA online Patient Safety Incident Report form: 2016
Cmpleting the NPA nline Patient Safety Incident Reprt frm: 2016 The infrmatin cntained within this dcument is in line with the current Data Prtectin Act (DPA) requirements. This infrmatin may be subject
More informationBP Thresholds for Medical Review
BP Threshlds fr Medical Review Wmen presents t GP pstnatally with high bld pressure r referred t GP by midwife GP t review patient n the same day if BP>150/100. If BP (dne by midwife) persistently 140-149/90-99,
More informationCONSENT FOR KYBELLA INJECTABLE FAT REDUCTION
CONSENT FOR KYBELLA INJECTABLE FAT REDUCTION INSTRUCTIONS This is an infrmed cnsent dcument which has been prepared t help yur Dctr infrm yu cncerning fat reductin with an injectable medicatin, its risks,
More information2017 Optum, Inc. All rights reserved BH1124_112017
1) What are the benefits t clients f encuraging the use f MAT? Withut MAT, 90% f individuals with Opiid Use Disrder (OUD) will relapse within ne year. With MAT, the relapse rate fr thse with OUD decreases
More informationBariatric Surgery FAQs for Employees in the GRMC Group Health Plan
Bariatric Surgery FAQs fr Emplyees in the GRMC Grup Health Plan Gergia Regents Medical Center and Gergia Regents Medical Assciates emplyees and eligible dependents wh are in the GRMC Grup Health Plan (Select
More informationCommissioning Policy: South Warwickshire CCG (SWCCG)
Cmmissining Plicy: Suth Warwickshire CCG (SWCCG) Treatment Indicatin Criteria FreeStyle Libre Flash Cntinuus Glucse Mnitring System Type I Diabetes Prir apprval must be requested frm the Individual Funding
More informationSwindon Joint Strategic Needs Assessment Bulletin
Swindn Jint Strategic Needs Assessment Bulletin Swindn Diabetes 2017 Key Pints: This JSNA gives health facts abut peple with diabetes r peple wh might get diabetes in Swindn. This helps us t plan fr medical
More informationPackage leaflet: Information for the user. Fragmin Graduated Syringe 10,000 IU/ml Solution for Injection dalteparin sodium
Package leaflet: Infrmatin fr the user Fragmin Graduated Syringe 10,000 IU/ml Slutin fr Injectin dalteparin sdium Read all f this leaflet carefully befre yu start using this medicine because it cntains
More informationSECTION O. MEDICATIONS
SECTION O. MEDICATIONS 1. NUMBER OF MEDICA TIONS (Recrd the number f different medicatins used in the last 7 days; enter "0" if nne used) O1. Number f Medicatins (7-day lk back) Intent: Prcess: Cding:
More informationAnnex III. Amendments to relevant sections of the Product Information
Changes t the Prduct infrmatin as apprved by the CHMP n 13 Octber 2016, pending endrsement by the Eurpean Cmmissin Annex III Amendments t relevant sectins f the Prduct Infrmatin Nte: These amendments t
More informationPain relief after surgery
Pain relief after surgery Imprtant infrmatin fr patients www.mchft.nhs.uk We care because yu matter This leaflet is designed t help yu cntrl any pain yu may have at hme fllwing yur peratin. Please read
More informationPackage leaflet: Information for the user. Fragmin 10,000 IU/1 ml and 10,000 IU/4 ml Solution for injection dalteparin sodium
Package leaflet: Infrmatin fr the user Fragmin 10,000 IU/1 ml and 10,000 IU/4 ml Slutin fr injectin dalteparin sdium Read all f this leaflet carefully befre yu start using this medicine because it cntains
More informationHospital Preparedness Checklist
Hspital Preparedness Checklist http://pandemicflu.gv Preparedness Subject 1. Structure fr planning and decisin making An internal, multidisciplinary planning cmmittee fr influenza preparedness has been
More informationBenefits for Anesthesia Services for the CSHCN Services Program to Change Effective for dates of service on or after July 1, 2008, benefit criteria
Benefits fr Anesthesia Services fr the CSHCN Services Prgram t Change Effective fr dates f service n r after July 1, 2008, benefit criteria fr anesthesia will change fr the Children with Special Health
More informationQUALITY AND SAFETY MEASURES UPDATE January 2016
CLINICAL EFFECTIVENESS/SAFETY M CORE MEASURES 2015 See attached Results QUALITY AND SAFETY MEASURES UPDATE January 2016 Jint Cmmissin and CMS Cre Measure Dashbard updated with mst recent data available:
More informationSUMMACARE COMMERCIAL MEDICATION REQUEST GUIDELINES. ANTI-OBESITY AGENTS Generic Brand HICL GCN Exception/Other QSYMIA 32515, 32744, 32746, 32745
Generic Brand HICL GCN Exceptin/Other NALTREXONE CONTRAVE ER 41389 /BUPROPION LORCASERIN BELVIQ 34733 PHENTERMINE PHENTERMINE 20691 20692 20693 20713 PHENTERMINE LOMAIRA 20715 PHENTERMINE/TO PIRAMATE GUIDELINES
More informationAppendix C Guidelines for treating status epilepticus in adults and children
Appendix C Guidelines fr treating status epilepticus in adults and children 1.1 Treating cnvulsive status epilepticus in adults General measures 1st stage (0 10 minutes) Secure airway and resuscitate Administer
More informationWaterloo Wellington Rehabilitative Care System Integrated Care Pathway for STROKE Stream of Care HYPERACUTE URGENT TIA and SECONDARY STROKE PREVENTION
Waterl Wellingtn Rehabilitative Care System Integrated Care Pathway fr STROKE Stream f Care HYPERACUTE URGENT TIA and SECONDARY STROKE PREVENTION Care Setting Activity Patients wh present t a cmmunity
More informationSignificance of Chronic Kidney Disease in 2015
1 Significance f Chrnic Kidney Disease in 2015 There is still a requirement within QOF t keep a register f peple with CKD stages 3-5. The ther CKD QOF targets have been retired. This is because CKD care
More informationPercutaneous Nephrolithotomy (PCNL)
Percutaneus Nephrlithtmy (PCNL) What is a percutaneus nephrlithtmy? is the mst effective f the cmmnly perfrmed prcedures fr kidney stnes. It is the best prcedure fr large and cmplex stnes. T perfrm this
More informationITP typically presents with the sudden appearance of a petechial rash, spontaneous bruising and/or bleeding in an otherwise well child.
Acute Immune Thrmbcytpenia Purpura (ITP) Backgrund Primary immune thrmbcytpenia (ITP) is an acquired immune mediated disrder characterised by islated thrmbcytpenia, defined as a peripheral bld platelet
More informationBEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE. RHEUMATOLOGY SHARED CARE GUIDELINE for DMARDs
BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE RHEUMATOLOGY SHARED CARE GUIDELINE fr DMARDs There are currently 6 Disease-mdifying anti rheumatic drugs (DMARDs) in rutine use by the Lutn & Dunstable
More informationWidening of funding restrictions for rituximab and eltrombopag
20 February 2014 Widening f funding restrictins fr rituximab and eltrmbpag PHARMAC is pleased t annunce the apprval f prpsals t widen the restrictin n rituximab use in DHB hspitals and expand the funding
More informationDRAFT Policy for the Management of Ear Wax
Clinical Cmmissining Grup (CCG) Treatment Plicy NHS Birmingham and Slihull Clinical Cmmissining Grup NHS Sandwell and West Birmingham Clinical Cmmissining Grup DRAFT Plicy fr the Management f Ear Wax 1
More informationYou may have a higher risk of bleeding if you take warfarin sodium tablets and:
MEDICATION GUIDE Warfarin (WAR-far-in) Sdium (SO-dee-um) Tablets USP The 7.5 mg tablets cntain FD&C Yellw N. 5 (tartrazine), which may cause allergic-type reactins (including brnchial asthma) in certain
More informationChildhood Immunization Status (NQF 0038)
Childhd Immunizatin Status (NQF 0038) EMeasure Name Childhd Immunizatin EMeasure Id Pending Status Versin Number 1 Set Id Pending Available Date N infrmatin Measurement Perid January 1, 20xx thrugh December
More informationFamily Medicine Clinical Pharmacy Forum Vol. 3, Issue 5 (September/October 2007)
1 Family Medicine Clinical Pharmacy Frum Vl. 3, Issue 5 (September/Octber 2007) Family Medicine Clinical Pharmacy Frum is a brief bi-mnthly publicatin frm the Family Medicine clinical pharmacists distributed
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial infrmatin prvided in this public disclsure synpsis is supplied fr infrmatinal purpses nly. Please nte that the results reprted in any single trial may nt reflect the verall ptential
More information3903 Fair Ridge Drive, Suite 209, Fairfax, VA Harry Byrd Hwy, Suite 285, Ashburn, VA *How did you hear about our program?
3903 Fair Ridge Drive, Suite 209, Fairfax, VA 22033 44121 Harry Byrd Hwy, Suite 285, Ashburn, VA 220147 *Hw did yu hear abut ur prgram? Patient Histry Patient Name: First Middle: Last: Address: City: State:
More informationPennsylvania Guidelines on the Use of Opioids to Treat Chronic Noncancer Pain
Pennsylvania Guidelines n the Use f Opiids t Treat Chrnic Nncancer Pain Chrnic pain is a majr health prblem in the United States, ccurring with a pintprevalence f abut ne-third f the US ppulatin.(1) Mre
More informationFormulary and Prescribing Guidelines
SECTION 7: MANAGEMENT OF DEMENTIA Frmulary and Prescribing Guidelines 7.1 Apprved drugs fr use in cgnitive impairment f Alzheimer s disease Drug 3 Frmulatin 3 Dse 3 Licensed 4 Dnepezil Tablets 5 mg, 10
More informationOsteoporosis Fast Facts
Osteprsis Fast Facts Fast Facts n Osteprsis Definitin Osteprsis, r prus bne, is a disease characterized by lw bne mass and structural deteriratin f bne tissue, leading t bne fragility and an increased
More informationCSHCN Services Program Benefits to Change for Outpatient Behavioral Health Services Information posted November 10, 2009
CSHCN Services Prgram Benefits t Change fr Outpatient Behaviral Health Services Infrmatin psted Nvember 10, 2009 Effective fr dates f service n r after January 1, 2010, benefit criteria fr utpatient behaviral
More informationMy Symptoms and Medical History for Adult Chronic Immune Thrombocytopenia (ITP)
My Symptms and Medical Histry fr Adult Chrnic Immune Thrmbcytpenia (ITP) Call t talk t a registered nurse 1-855-7Nplate (1-855-767-5283), Mnday Friday, 9:00 AM 9:00 PM ET Indicatin Nplate is a man-made
More informationReferral Criteria: Inflammation of the Spine Feb
Referral Criteria: Inflammatin f the Spine Feb 2019 1 5.7. Inflammatin f the Spine Backgrund Ankylsing spndylitis and axial spndylarthrpathy are fund in arund 0.3-1.2% f the ppulatin. Spndylarthritis encmpasses
More information1.11 INSULIN INFUSION PUMP MANAGEMENT INPATIENT
WOMEN AND NEWBORN HEALTH SERVICE CLINICAL GUIDELINES SECTION A: GUIDELINES RELEVANT TO OBSTETRICS AND GYNAECOLOGY 1 STANDARD PROTOCOLS 1.11 INSULIN INFUSION PUMP MANAGEMENT - INPATIENT Authrised by: OGCCU
More informationFrequently Asked Questions: IS RT-Q-PCR Testing
Questins 1. What is chrnic myelid leukemia (CML)? 2. Hw des smene knw if they have CML? 3. Hw is smene diagnsed with CML? Frequently Asked Questins: IS RT-Q-PCR Testing Answers CML is a cancer f the bld
More informationObesity/Morbid Obesity/BMI
Obesity/mrbid besity/bdy mass index (adult) Obesity/Mrbid Obesity/BMI Definitins and backgrund Diagnsis cde assignment is based n the prvider s clinical judgment and crrespnding medical recrd dcumentatin
More informationLEVEL OF CARE GUIDELINES: INTENSIVE BEHAVIORAL THERAPY/APPLIED BEHAVIOR ANALYSIS FOR AUTISM SPECTRUM DISORDER HAWAII MEDICAID QUEST
OPTUM LEVEL OF CARE GUIDELINES: INTENSIVE BEHAVIORAL THERAPY / APPLIED BEHAVIOR ANALYSIS FOR AUTISM SPECTRUM DISORDER HAWAII MEDICAID QUEST LEVEL OF CARE GUIDELINES: INTENSIVE BEHAVIORAL THERAPY/APPLIED
More informationTOP TIPS Lung Cancer Update Dr Andrew Wight Consultant respiratory Physician - WUTH
Tpic Circulatin list In case f query please cntact Executive Summary TOP TIPS Lung Cancer Update Dr Andrew Wight Cnsultant respiratry Physician - WUTH All Wirral GP s JaneFletcher2@nhs.net Dear Clleagues,
More informationHigh Performance Network Quality Criteria for Designation
Selected quality measures include: Specialty Measure Descriptin Allergy / Immunlgy Asthma Drug Mgt Vaccine Pneumnia Vaccine High Perfrmance Netwrk Quality Criteria fr Designatin AvMed has selected certain
More informationCancer Association of South Africa (CANSA)
Cancer Assciatin f Suth Africa (CANSA) Fact Sheet and Psitin Statement n Cannabis in Suth Africa Intrductin Cannabis is a drug that cmes frm Indian hemp plants such as Cannabis sativa and Cannabis indica.
More informationMethadone Maintenance Treatment for Opioid Dependence
POLICY STATEMENT Methadne Maintenance Treatment fr Opiid Dependence APPROVED BY COUNCIL: May 2010 PUBLICATION DATE: Dialgue, Issue 2, 2010 Disclaimer: As f May 19, 2018 physicians n lnger require an exemptin
More informationBedfordshire and Hertfordshire DRAFT Priorities forum statement Number: Subject: Prostatism Date of decision: January 2010 Date of review:
Bedfrdshire and Hertfrdshire DRAFT Pririties frum statement Number: Subject: Prstatism Date f decisin: January 2010 Date f review: Referral criteria Mst men with lwer urinary tract symptms due t benign
More informationDrug Therapy Guidelines
Drug Therapy Guidelines Orencia (abatacept) Applicable Medical Benefit x Effective: 2/21/18 Pharmacy- Frmulary 1 x Next Review: 12/18 Pharmacy- Frmulary 2 x Date f Origin: 11/28/06 Pharmacy- Frmulary 3/Exclusive
More informationGeneric Immunosuppressants in the Specialist Area of Transplantation Consensus on Implications and Practical Recommendations
Dear Clleague Generic Immunsuppressants in the Specialist Area f Transplantatin Cnsensus n Implicatins and Practical Recmmendatins Executive Summary Slid-rgan transplants are the best pssible treatment
More informationFee Schedule - Home Health Care- 2015
Fee Schedule - Hme Health Care- 2015 01/01/2015 1600 E Century Ave Ste 1 PO Bx 5585 Bismarck ND 58506-5585 www.wrkfrcesafety.cm Cpyright Ntice The five character cdes included in the Nrth Dakta Fee Schedule
More informationCardiac Rehabilitation Services
Dcumentatin Guidance N. DG1011 Cardiac Rehabilitatin Services Revisin Letter A 1.0 Purpse The Centers fr Medicare and Medicaid Services (CMS) has detailed specific dcumentatin requirements fr Cardiac Rehabilitatin
More informationCLINICAL MEDICAL POLICY
Plicy Name: Plicy Number: Respnsible Department(s): CLINICAL MEDICAL POLICY Supervised Exercise Therapy fr Peripheral Artery Disease (PAD) MP-077-MD-DE Medical Management Prvider Ntice Date: 01/15/2019
More informationALCAT FREQUENTLY ASKED QUESTIONS
1. Is fasting required befre taking the Alcat Test? N. It is recmmended t drink water and t avid stimulants like caffeine prir t the test. 2. With regard t testing children, must a child be a certain age
More informationDrug Therapy Guidelines
Applicable Medical Benefit x Effective: 5/1/18 Pharmacy- Frmulary 1 x Next Review: 3/18 Pharmacy- Frmulary 2 x Date f Origin: 4/99 Gnadtrpin-Releasing Hrmne Agnists- Eligard, Luprn, Luprn-Dept, Luprn Dept-Ped,
More informationTHROUGH 1979, immunosuppressive
Five-Year Survival After Liver Transplantatin THROUGH 1979, immunsuppressive therapy fr liver transplantatin at ur center was with aathiprine (r cyclphsphamide) and sterids, t which antilymphcyte glublin
More informationResponse to. type 2 vaccine-derived polioviruses. prior to global topv withdrawal. Interim Guidelines
Respnse t type 2 vaccine-derived pliviruses prir t glbal topv withdrawal Interim Guidelines August 2015 GPEI peratinal guidance nte August 2015 Summary Prepare fr prmpt actin fr any area r ppulatin at
More informationSafety of HPV vaccination: A FIGO STATEMENT
FIGO Statement n HPV Vaccinatin Safety, August 2nd, 2013 Safety f HPV vaccinatin: A FIGO STATEMENT July, 2013 Human papillmavirus vaccines are used in many cuntries; glbally, mre than 175 millin dses have
More informationWound Care Equipment and Supply Benefits to Change for Texas Medicaid July 1, 2018
Wund Care Equipment and Supply Benefits t Change fr Texas Medicaid July 1, 2018 Infrmatin psted May 11, 2018 Nte: Texas Medicaid managed care rganizatins (MCOs) must prvide all medically necessary, Medicaid-cvered
More informationDrug Class Review: Long-acting muscarinic antagonists (LAMAs) for treatment of chronic obstructive pulmonary disease (COPD)
Drug Class Review: Lng-acting muscarinic antagnists (LAMAs) fr treatment f chrnic bstructive pulmnary disease (COPD) Cmprehensive Research Plan: Pharmacepidemilgy Unit April 10 th, 2014 ODPRN Drug Class
More informationM.R.C.Path. causes to the raised plasma urea in patients admitted
Pstgradcuate Medical Jurnal (January 1979) 55, 1-14 The cause f the raised plasma urea f acute heart failure R D THOMAS MRCP D B MORGAN MRCPath ALISON NWILL AIMLS Departments f Cardilgy and Chemical Pathlgy,
More informationShared Care Protocol for the prescribing and monitoring of maintenance doses of azathioprine in Inflammatory Bowel Disease
Apprved by the Bedfrdshire and Lutn Jint Prescribing Cmmittee (JPC) December 2013, Review date December 2016 Bedfrdshire and Lutn Jint Prescribing Cmmittee Shared Care Prtcl fr the prescribing and mnitring
More informationBreast Cancer Awareness Month 2018 Key Messages (as of June 6, 2018)
Breast Cancer Awareness Mnth 2018 Key Messages (as f June 6, 2018) In this dcument there are tw sectins f messages in supprt f Cancer Care Ontari s Breast Cancer Awareness Mnth 2018: 1. Campaign key messages
More informationSchool Medication Authorization Form. School Grade Teacher. Emergency Phone No: To be completed by the student's physician: Name of Medication:
Schl Medicatin Authrizatin Frm Student's Name Address Birth Date Hme Phne Schl Grade Teacher Emergency Phne N: T be cmpleted by the student's physician: Name f Medicatin: Dsage Frequency Time t be given
More informationQ 5: Is relaxation training better (more effective than/as safe as) than treatment as usual in adults with depressive episode/disorder?
updated 2012 Relaxatin training Q 5: Is relaxatin training better (mre effective than/as safe as) than treatment as usual in adults with depressive episde/disrder? Backgrund The number f general health
More informationShared Care Protocol for the prescribing and monitoring of maintenance doses of azathioprine in Inflammatory Bowel Disease
Bedfrdshire and Lutn Jint Prescribing Cmmittee Shared Care Prtcl fr the prescribing and mnitring f maintenance dses f azathiprine in Inflammatry Bwel Disease This prtcl applies t patients under the care
More information5.0: Rare Bleeding Disorders
5.0: Rare Bleeding Disrders 5.1: General Infrmatin Rare bleeding disrders (RBDs) include deficiencies f factrs I (Fibringen), II, V, VII, X, XI and XIII. These deficiencies can be severe r mild. Severe
More informationNational Hospital Inpatient Quality Reporting Measures Specifications Manual Release Notes
Natinal Hspital Inpatient Quality Reprting Measures Specificatins Manual Release Ntes Fr Manual Versin: 5.5 Cmpleted: June 14, 2018 Guidelines fr Using Release Ntes The Release Ntes prvides mdificatins
More informationRelated Policies None
Medical Plicy MP 3.01.501 Guidelines fr Cverage f Mental and Behaviral Health Services Last Review: 8/30/2017 Effective Date: 8/30/2017 Sectin: Mental Health End Date: 08/19/2018 Related Plicies Nne DISCLAIMER
More informationSolid Organ Transplant Benefits to Change for Texas Medicaid
Slid Organ Transplant Benefits t Change fr Texas Medicaid Infrmatin psted February 13, 2015 Nte: All new and updated prcedure cdes and their assciated reimbursement rates are prpsed benefits pending a
More informationStructured Assessment using Multiple Patient. Scenarios (StAMPS) Exam Information
Structured Assessment using Multiple Patient Scenaris (StAMPS) Exam Infrmatin 1. Preparing fr the StAMPS assessment prcess StAMPS is an assessment mdality that is designed t test higher rder functins in
More informationCoronary Artery Disease (CAD): Beta Blocker Therapy for CAD Patients with Prior Myocardial Infarction (MI) (NQF 0070)
Crnary Artery Disease (CAD): Beta Blcker Therapy fr CAD Patients with Prir Mycardial Infarctin (MI) (NQF 0070) EMeasure Name Crnary Artery Disease EMeasure Id Pending (CAD): Beta Blcker Therapy fr CAD
More informationInfluenza (Flu) Fact Sheet
Influenza (Flu) Fact Sheet What is the flu? The flu is a cntagius respiratry illness caused by influenza viruses. It can cause mild t severe illness, and at times can lead t death. Sme peple, such as lder
More informationGUIDANCE DOCUMENT FOR ENROLLING SUBJECTS WHO DO NOT SPEAK ENGLISH
GUIDANCE DOCUMENT FOR ENROLLING SUBJECTS WHO DO NOT SPEAK ENGLISH Aurra Health Care s Research Subject Prtectin Prgram (RSPP) This guidance dcument will utline the prper prcedures fr btaining and dcumenting
More informationHerbal Medicines: Traditional Herbal Registration
Herbal Medicines: Traditinal Herbal Registratin In the UK, cmpanies can nly sell herbal medicines with the apprpriate prduct licence, as fllws: A full marketing authrisatin based n the safety, quality
More informationACRIN 6666 Screening Breast US Follow-up Assessment Form
Screening Breast US Fllw-up Assessment Frm N. Instructins: The frm is cmpleted at 12, 24 and 36 mnths pst initial n study mammgraphy and ultrasund by the Radilgist r RA. Reprt all interim infrmatin related
More informationBRCA1 and BRCA2 Mutations
BRCA1 and BRCA2 Mutatins ROBERT LEVITT, MD JESSICA BERGER-WEISS, MD ADRIENNE POTTS, MD HARTAJ POWELL, MD, MPH COURTNEY LEVENSON, MD LAUREN BURNS, MSN, RN, WHNP OBGYNCWC.COM v Cancer is a cmplex disease
More informationAppendix 1 Example of Homely Remedy Policy
Appendix 1 Example f Hmely Remedy Plicy Hmely Remedy Plicy - EXAMPLE This plicy applies t (insert name f Care Hme) Definitin A hmely (r husehld) remedy is a medicinal prduct fr the shrt-term treatment
More informationPolicy Guidelines: Genetic Testing for Carrier Screening and Reproductive Planning
Plicy Guidelines: Genetic Testing fr Carrier Screening and Reprductive Planning Cntents Overview... 1 Cverage guidelines... 2 General cverage guidelines... 2 Rutine carrier screening... 2 Carrier screening
More informationDental Benefits. Under the TeamstersCare Plan, you and your eligible dependents have three basic options when you need dental care.
Dental Benefits Under the TeamstersCare Plan, yu and yur eligible dependents have three basic ptins when yu need dental care. Optin #1: TeamstersCare Dentists. Yu can use ur in-huse Charlestwn, Chelmsfrd,
More informationCorporate Governance Code for Funds: What Will it Mean?
Crprate Gvernance Cde fr Funds: What Will it Mean? The Irish Funds Industry Assciatin has circulated a draft Vluntary Crprate Gvernance Cde fr the Funds Industry in Ireland. 1. Backgrund On 13 June 2011,
More informationGuidelines for the Admission of Children and Young People with an Eating Disorder
Guidelines fr the Admissin f Children and Yung Peple with an Eating Disrder This dcument is designed t be used by clinicians lcated in hspitals f wards withut specialist eating disrder facilities, t guide
More informationTriumeq (abacavir, dolutegravir and lamivudine) Product Backgrounder for US Media
Triumeq (abacavir, dlutegravir and lamivudine) Prduct Backgrunder fr US Media What is Triumeq and wh is Triumeq fr? Triumeq (abacavir 600mg, dlutegravir 50mg and lamivudine 300mg) is the first dlutegravir-based
More informationThis standard operating procedure applies to stop smoking services provided by North 51.
Authr Name/Title Melanie McIlvar, Bid Develpment Manager Authr Signature Date: 4 th September 2017 Apprver Name/Title Jasn Shelley, Grup Directr f QA/RA Apprver Signature Date: 4 th September 2017 Issue
More informationWHAT IS HEAD AND NECK CANCER FACT SHEET
WHAT IS HEAD AND NECK CANCER FACT SHEET This infrmatin may help answer sme f yur questins and help yu think f ther questins that yu may want t ask yur cancer care team; it is nt intended t replace advice
More informationMEDICATION GUIDE Pioglitazone and Metformin Hydrochloride (PYE o GLI ta zone and met FOR min HYE-droe- KLOR-ide)Tablets, USP
MEDICATION GUIDE Piglitazne and Metfrmin Hydrchlride (PYE GLI ta zne and met FOR min HYE-dre- KLOR-ide)Tablets, USP Read this Medicatin Guide carefully befre yu start taking piglitazne and metfrmin hydrchlride
More informationPrinted copies of this document may not be up to date, obtain the most recent version from Author Position
Printed cpies f this dcument may nt be up t date, btain the mst recent versin frm www.cats.nhs.uk Children s Acute Transprt Service Clinical Guidelines Diabetic Ketacidsis Dcument Cntrl Infrmatin Authr
More informationClinical Study Synopsis
Clinical Study Synpsis This Clinical Study Synpsis is prvided fr patients and healthcare prfessinals t increase the transparency f Bayer's clinical research. This dcument is nt intended t replace the advice
More informationOTHER AND UNSPECIFIED DISORDERS
OPTUM COVERAGE DETERMINATION GUIDELINE OTHER AND UNSPECIFIED DISORDERS Guideline Number: BH727OUD_102017 Effective Date: Octber, 2017 Table f Cntents Page INSTRUCTIONS FOR USE... 1 BENEFIT CONSIDERATIONS...
More informationOpioid Analgesics PA Request Provider Checklist
WVP Health Authrity Updated 05-12-2015 Opiid Analgesics PA Request Prvider Checklist *** If pssible, please include the fllwing infrmatin with PA requests fr piid analgesics. Including the requested infrmatin
More informationMEASURE #10: PLAN OF CARE FOR MIGRAINE OR CERVICOGENIC HEADACHE DEVELOPED OR REVIEWED Headache
MEASURE #10: PLAN OF CARE FOR MIGRAINE OR CERVICOGENIC HEADACHE DEVELOPED OR REVIEWED Headache Measure Descriptin All patients diagnsed with migraine headache r cervicgenic headache wh had a headache management
More informationPediatric and adolescent preventive care and HEDIS *
Pediatric and adlescent preventive care and HEDIS * * HEDIS is a registered trademark f the Natinal Cmmittee fr Quality Assurance (NCQA). UniCare Health Plan f West Virginia, Inc. Healthcare Effectiveness
More informationService Change Process. Gateway 1 High-level Proposition. Innovation project name: Patient Self-Monitoring/Management of Warfarin
Service Change Prcess Gateway 1 High-level Prpsitin Innvatin prject name: Patient Self-Mnitring/Management f Warfarin NHS Bury Please describe the service change being prpsed. Please describe what service(s)
More informationDrug Therapy Guidelines
Drug Therapy Guidelines Applicable* Hereditary Angiedema (HAE) Agents: Berinert (C1 esterase inhibitr [human]), Cinryze (C1 esterase inhibitr [human]), Haegarda (C1 esterase inhibitr [human]) Kalbitr (ecallantide),
More informationHEALTH SURVEILLANCE INDICATORS: CERVICAL CANCER SCREENING. Public Health Relevance. Highlights.
HEALTH SURVEILLANCE INDICATORS: CERVICAL CANCER SCREENING Public Health Relevance Cervical cancer is 90% preventable by having regular Papaniclau (Pap) tests. The Pap test, als knwn as a cervical smear,
More informationUrinary tract infection (lower) - women - Management
Urinary tract infectin (lwer) - wmen - Management Scenari: Cystitis in wmen wh are nt pregnant Hw shuld I manage a wman with suspected cystitis? Cnvey a psitive apprach and reassure the wman that cystitis
More informationHeart Failure (HF): Angiotensin Converting Enzyme (ACE) Inhibitor or
Heart Failure (HF): Angitensin Cnverting Enzyme (ACE) Inhibitr r Angitensin Receptr Blcker (ARB) Therapy fr Left Ventricular Systlic Dysfunctin (LVSD) (NQF 0081) EMeasure Name Heart Failure (HF): Angitensin
More informationMEDICATION GUIDE Pioglitazone (pie-oh-glit-ah-zohn) and Metformin (met-fore-min) Hydrochloride Tablets USP
MEDICATION GUIDE Piglitazne (pie-h-glit-ah-zhn) and Metfrmin (met-fore-min) Hydrchlride Tablets USP Read this Medicatin Guide carefully befre yu start taking piglitazne and metfrmin hydrchlride tablets
More information